Orchestra BioMed Holdings, Inc.
OBIO
NASDAQ·Healthcare·Biotechnology·Mkt cap $304.2M
$5.08
▲ +7.17%
P/E
-4.34
Mkt Cap
$304.2M
52-Wk Range
$2.20–$5.78
52-Week Range
$2.20 - $5.78
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 86.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Strategic partnerships with Medtronic and Terumo Corporation for development and commercialization
- Proprietary neuromodulation and drug-delivery technology platforms
- Focus on minimally invasive solutions with strong clinical differentiation
- Experienced management team with deep biomedical device industry expertise
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Clinical trial progression and FDA regulatory approvals for BackBeat and Virtue products
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+30.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying OBIO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 10, 2026
Reported EPS of -$0.38 vs -$0.39 consensus (+3.1% surprise). Revenue of $88.0K vs $137.7K expected (-36.1%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+3.1%
Revenue trend · last 8Q
—
—
—
—
+7%
-13%
+12120%
-89%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q2 26
$778.0K
$987.0K
$253.0K
$868.0K
$836.0K
$861.0K
$30.9M
$88.0K
Margins · last 8Q
Gross
71.6%
Operating
—
Profit
-27362.5%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: B. Riley · May 19, 2026
vs Industry
How OBIO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.